# Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis

> **NCT05948982** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Asia Cell Therapeutics (Shanghai) Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Decompensated Liver Cirrhosis

## Interventions

- **BIOLOGICAL:** Human Umbilical Cord Mesenchymal Stem Cells

## Key facts

- **NCT ID:** NCT05948982
- **Lead sponsor:** Asia Cell Therapeutics (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05948982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05948982, "Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05948982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*